Vitiligo: new etiology-based treatments
Keywords:
vitiligo, calcipotriol, tacrolimus, pimecrolimus, catalaseAbstract
Vitiligo is an acquired depigmentary disorder characterized by a chronic and progressive loss of melanocytes from the epidermis. The etiopathogenesis of vitiligo is still not fully understood, and the major theories include melanocyte destruction (autoimmune, neural and impaired redox status) and melanocyte inhibition or defective adhesion. Recently a new theory, melanocytorrhagy, was forwarded. In this review are also discussed the new etiology-based treatments, mainly topical calcipotriol, topical immunomodulators and topical catalase.References
Bleehen SS, Anstey AV. Disorders of skin colour. In: Burns T, Breathnach S, Cox N, Griffiths C, eds. Rook’s Textbook of Dermatology, 7th edn. Oxford: Blackwell Science; 2004. p. 39.1-39.68.
Gauthier Y, Cario-Andre M, Taieb A. A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? Pigment Cell Res 2004; 16: 322-32.
Porter J, Hill-Beuf A, Lerner A, Nordlund J. Response to cosmetic disfigurement: patients with vitiligo. Cutis 1987; 39: 493-4.
Noor SM, Khurshid K, Mahmood T, Haroon TS. Quality of life in vitiligo patients. J Pak Assoc Dermatol 2004; 14: 55-8.
Grimes PE. New insights and new therapies in vitiligo. JAMA 2005 ; 293: 730-5.
Wang X, Erf GF. Apoptosis in feathers of Smyth line chickens with autoimmune vitiligo. J Autoimmun 2004; 22: 21-30.
Gauthier Y, Cario-Andre M, Lepreux S et al. Melanocyte detachment after skin friction in non lesional skin of patients with generalized vitiligo. Br J Dermatol 2003; 148: 95-101.
Wang X, Erf GF. Apoptosis in feathers of Smyth line chickens with autoimmune vitiligo. J Autoimmun 2004; 22: 21-30.
Bowen AR, Hanks AN, Allen SM et al. Apoptosis regulators and responses in human melanocytic and keratinocytic cells. J Invest Dermatol 2003; 100: 48-55.
Le Poole IC, Wankowicz-Kalinska A, van den Wijngaard RM et al. Autoimmune aspects of depigmentation in vitiligo. J Investig Dermatol Symp Proc 2004 ; 9: 68-72.
Wankowicz-Kalinska A, van den Wijngaard RM, Tigges BJ et al. Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest 2003; 83: 683-95.
Cucchi ML, Frattini P, Santagostino G et al. Catecholamines increase in the urine of non-segmental vitiligo especially during its active phases. Pigment Cell Res 2003; 16: 111-6.
Morrone A, Piccardo M, de Luca C et al. Catecholamines and vitiligo. Pigment Cell Res 1992; 5: 65-9.
Goth L, Rass P, Pay A. Catalase enzyme mutations and their association with diseases. Mol Diagn 2004; 8: 141-9.
Hasse S, Gibbons NC, Rokos H Perturbed 6-tetrahydrobiopterin recycling via decreased dihydropteridine reductase in vitiligo: more evidence for H2O2 stress. J Invest Dermatol 2004; 122: 307-13.
Schallreuter KU, Wood JM, Lemke KR, Levenig C. Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB-exposure: a case study on 33 patients. Dermatology 1995; 190: 223-9.
Schallreuter KU, Pittelkow MP. Defective calcium uptake in keratinocytes cell cultures from vitiligo skin. Arch Dermatol Res 1988; 280: 137-9.
Tobin DJ, Swanson NN, Pittelkow MR et al. Melanocytes are not absent in lesional skin of long duration vitiligo. J Pathol 2000; 191: 407-16.
Morelli JG, Yohn JJ, Zekman T, Norris DA. Melanocyte movement in vitro: role of matrix protein and integrin receptors. J Invest Dermatol 1993; 101: 605-8.
Jimbow K, Chen H, Park JS, Thomas PD. Increased sensitivity of melanocytes to oxidative stress and abnormal expression of tyrosinase-related protein in vitiligo. Br J Dermatol 2001; 144: 55-65.
Guilhou J1. Calcipotriol. Ann Dermatol 2001; 128: 229-37.
Parsad D, Saini R, Vema N. Combination of PUVASOL and topical calcipotriol in vitiligo. Dermatology 1998; 197: 167- 70.
Ameen M, Exarchou V, Chu AC. Topical calcipotriol as monotherapy and in combination with psoralen plus ultraviolet A in the treatment of vitiligo. Br J Dermatol 2001; 145: 476-9.
Ermis O, Alpsoy E, Cetin L, Yilmaz E. Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo-controlled double-blind study. Br J Dermatol 2001; 145: 472-5.
Chiaverini C, Passeron T, Ortonne JP. Treatment of vitiligo by topical calcipotriol. J Eur Acad Dermatol 2002; 16: 137-8.
Baysal V, Yildirim M, Erel A, Kesici D. Is the combination of Calcipotriol and PUVA effective in vitiligo? J Eur Acad Dermatol Venereol 2003; 17: 299-302.
Shahzad A. Topical Calcipotriol alone vs. oral PUVA and topical Calcipotriol in the treatment of vitiligo (Dissertation for fellowship). Karachi: College of Physicians and Surgeons Pakistan; 2003.
Travis LB, Silverberg NB. Calcipotriene and corticosteroid combination therapy for vitiligo. Pediatr Dermatol 2004; 21: 495-8.
Kullavanijaya P, Lim HW. Topical calcipotriol and narrow-band ultraviolet B in the treatment of vitiligo. Photodermatol Photoimmunol Photomed 2004: 20: 248-51.
Ada S, Sabin S, Boztepe G et al. No additional effect of topical ca1cipotriol on narrow-band UVB phototherapy in patients with generalized vitiligo. Photodermatol Photoimmunol Photomed 2005; 21: 79-83.
Hartmann A, Lurz C, Hamm H et al. Narrow-band UVB311 nm vs. broad-band UVB therapy in combination with topical calcipotriol vs. placebo in vitiligo. Int J Dermatol 2005; 44: 736-42.
Bruynzeel DP, Hol CW, Nieboer C. Allergic contact dermatitis to calcipotriol. Br J Dermatol 1992; 127: 66.
Molin L. Contact dermatitis after calcipotriol and patch test evaluation. Acta Derm Venereol 1996; 76: 163-4.
Kragballe K, Barnes L, Hamberg KJ et al. Ca1cipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. Br J Dermatol 1998; 139: 649-54.
Lebwohl M, Hecker D, Martinez J et al. Interaction between calcipotriol and ultraviolet light. J Am Acad Dermatol 1997; 37: 93-5.
Molin L and the Calcipotriol-UVB study group. Does addition of topical calcipotriol to UVB increase the risk of irritant reactions in psoriasis? Acta Derm Venereol 1997; 77: 401-2.
McKenna KE, Stems RS. Photosensitivity associated with combined UVB and ca1cipotriene therapy. Arch Dermatol 1995; 131: 1305-7.
Kostovic K, Pasic A. New treatment modalities for vitiligo: focus on topical immunomodulators. Drugs 2005; 65: 447-59.
Tocci MJ, Matkovich DA, Collier KA et al. The immunosuppressant FK-506 inhibits expression of early T-cell activation genes. J Immunol 1989; 143: 718-26.
Grimes PE, Morris R, Avaniss-Aghajani E et al. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004 ; 51: 52-61.
Tanghetti EA. Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patients series. Cutis 2003; 71: 158-62.
Silverberg NB, Lin P, Travis L et al. Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases. J Am Acad Dermatol 2004; 51: 760-6.
Kanwar AJ, Dogra S, Parsad D. Topical Tacrolimus for treatment of childhood vitiligo in Asians. Clin Exp Dermatol 2004; 29: 589-92.
Lepe V, Moncada B, Castanedo-Cazares JP et al. A double-blind randomized trial of 0.1 % tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139: 581-5.
Kawalek AZ, Spencer JM, Phelps RG. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol Surg 2004; 30: 130-5.
Passeron T, Ostovari N, Zakaria W et al. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol 2004; 140: 1065-9.
Coskun B, Saral Y, Turgut D. Topical 0.05% clobetasol propionate vs. 1% pimecrolimus ointment in vitiligo. Eur J Dermatol 2005; 15: 88-91.
Prats Caelles I, Herranz Pinto P, de Ayala Casado EL, de Lucas Laguna R. Focal hypertrichosis during topical tacrolimus therapy for childhood vitiligo. Pediatr Dermatol 2005; 22: 86-7.
FDA Public Health Advisory. Elidel (Pimecrolimus) cream and Protopic (Tacrolimus) ointment. March 10, 2005.
Patel DC, Evans A V, Hawk JLM. Topical pseudocatalase mousse and narrowband UVB phototherapy is not effective for vitiligo: an open, single-centre study. Clin Exp Dermatol 2002; 27: 641-4.
Khemis A, Ortonne lP. Study comparing a vegetal extract with superoxide dismutase and catalase activities (ViTiX®) plus selective UVB phototherapy versus an excipient plus selective UVB phototherapy in the treatment of vitiligo vulgaris. Nouv Dermatol 2004; 23: 2-3.
Zhang Y, Wang JZ, Wu YJ, Li WG, Anti-inflammatory effect of recombinant human superoxide dismutase in rats and mice and its mechanism. Acta Pharmacol Sin 2002; 23: 439-44.
Chang SC, Kao MC, Fu MT, Lin, CT, Modulation of NO and cytokines in microglyal cells by Cu/Zn superoxide dismutase. Free Radic BioI Med 2001; 31: 1084-9.
Lange RW, Germolic DR, Foley JF, Luster MI. Antioxidants attenuate anthralin¬induced skin inflammation in BALB/c mice: role of specific Pro inflammatory cytokines. J Leukoc Biol 1998; 64: 170-6.
